Treatment of rheumatoid arthritis with methotrexate in Congolese patients
Identifieur interne : 001145 ( Main/Exploration ); précédent : 001144; suivant : 001146Treatment of rheumatoid arthritis with methotrexate in Congolese patients
Auteurs : J. J. Malemba ; J. M. Mbuyi Muamba ; J. Mukaya ; X. Bossuyt [Belgique] ; P. Verschueren [Belgique] ; R. Westhovens [Belgique]Source :
- Clinical Rheumatology [ 0770-3198 ] ; 2013-09-01.
English descriptors
- KwdEn :
Abstract
Abstract: Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA) but data concerning the effectiveness of treatment with this compound are lacking in the Congolese population. In the present study, the evolution of RA in Congolese patients on MTX treatment is reported from before disease-modifying antirheumatic drug (DMARD) initiation till 20 months later. All consecutive DMARD-naïve RA patients (ACR 1987 criteria) attending the rheumatology unit of the University Hospital of Kinshasa from January 2008 to September 2010 were included. All were treated with MTX (started at 7.5 mg/week) and bridging steroids (started at 30mg/day). Treatment adaptations of MTX and concomitant drugs are reported as well as evolution of disease activity (DAS28-ESR), functionality (Health Assessment Questionnaire), radiological damage, and safety over 20 months. Of 98 patients recruited, more than one third were lost at follow-up. A follow-up visit at 20 months was available for 51 patients. These 48 women and 3 men had a mean age of 51.2 ± 13 years and a mean delay from symptom onset till their first visit of 3.2 years. At 20 months, the average MTX dose was 9.7 mg weekly. A second DMARD was added in three patients. The average dose of prednisone at 20 months was 7.5 mg daily. A significant improvement of DAS28 and functional disability was observed and 35.3 % of patients entered remission (DAS28 <2.6). A progression of X-ray damage was observed in one third of patients. Two patients had to stop MTX because of severe side effects and two patients developed diabetes. Methotrexate and bridging steroids therapy is effective also in sub-Saharan Africa but the average weekly MTX dose remains low. Implementation of a regular follow-up is a major issue.
Url:
DOI: 10.1007/s10067-013-2269-4
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000299
- to stream Istex, to step Curation: 000299
- to stream Istex, to step Checkpoint: 000197
- to stream Main, to step Merge: 001146
- to stream Main, to step Curation: 001145
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of rheumatoid arthritis with methotrexate in Congolese patients</title><author><name sortKey="Malemba, J J" sort="Malemba, J J" uniqKey="Malemba J" first="J. J." last="Malemba">J. J. Malemba</name></author><author><name sortKey="Mbuyi Muamba, J M" sort="Mbuyi Muamba, J M" uniqKey="Mbuyi Muamba J" first="J. M." last="Mbuyi Muamba">J. M. Mbuyi Muamba</name></author><author><name sortKey="Mukaya, J" sort="Mukaya, J" uniqKey="Mukaya J" first="J." last="Mukaya">J. Mukaya</name></author><author><name sortKey="Bossuyt, X" sort="Bossuyt, X" uniqKey="Bossuyt X" first="X." last="Bossuyt">X. Bossuyt</name></author><author><name sortKey="Verschueren, P" sort="Verschueren, P" uniqKey="Verschueren P" first="P." last="Verschueren">P. Verschueren</name></author><author><name sortKey="Westhovens, R" sort="Westhovens, R" uniqKey="Westhovens R" first="R." last="Westhovens">R. Westhovens</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AB2D15A11890979C03CDDE657DF5F5251C5549BA</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1007/s10067-013-2269-4</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-JH7SSRDG-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000299</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000299</idno><idno type="wicri:Area/Istex/Curation">000299</idno><idno type="wicri:Area/Istex/Checkpoint">000197</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000197</idno><idno type="wicri:doubleKey">0770-3198:2013:Malemba J:treatment:of:rheumatoid</idno><idno type="wicri:Area/Main/Merge">001146</idno><idno type="wicri:Area/Main/Curation">001145</idno><idno type="wicri:Area/Main/Exploration">001145</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of rheumatoid arthritis with methotrexate in Congolese patients</title><author><name sortKey="Malemba, J J" sort="Malemba, J J" uniqKey="Malemba J" first="J. J." last="Malemba">J. J. Malemba</name><affiliation><wicri:noCountry code="subField">Congo</wicri:noCountry></affiliation></author><author><name sortKey="Mbuyi Muamba, J M" sort="Mbuyi Muamba, J M" uniqKey="Mbuyi Muamba J" first="J. M." last="Mbuyi Muamba">J. M. Mbuyi Muamba</name><affiliation><wicri:noCountry code="subField">Congo</wicri:noCountry></affiliation></author><author><name sortKey="Mukaya, J" sort="Mukaya, J" uniqKey="Mukaya J" first="J." last="Mukaya">J. Mukaya</name><affiliation><wicri:noCountry code="subField">Congo</wicri:noCountry></affiliation></author><author><name sortKey="Bossuyt, X" sort="Bossuyt, X" uniqKey="Bossuyt X" first="X." last="Bossuyt">X. Bossuyt</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Experimental Laboratory Immunology, Department of Medical Diagnostic Sciences, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Verschueren, P" sort="Verschueren, P" uniqKey="Verschueren P" first="P." last="Verschueren">P. Verschueren</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Rheumatology, Neuromusculo-skeletal Research Unit, Department of Development and Regeneration, KU Leuven, Herestraat 49, 3000, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Westhovens, R" sort="Westhovens, R" uniqKey="Westhovens R" first="R." last="Westhovens">R. Westhovens</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Rheumatology, Neuromusculo-skeletal Research Unit, Department of Development and Regeneration, KU Leuven, Herestraat 49, 3000, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Belgique</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="ISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><imprint><publisher>Springer London</publisher><pubPlace>London</pubPlace><date type="published" when="2013-09-01">2013-09-01</date><biblScope unit="volume">32</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1323">1323</biblScope><biblScope unit="page" to="1327">1327</biblScope></imprint><idno type="ISSN">0770-3198</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0770-3198</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DR Congo</term><term>Evolution</term><term>Methotrexate</term><term>Rheumatoid arthritis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA) but data concerning the effectiveness of treatment with this compound are lacking in the Congolese population. In the present study, the evolution of RA in Congolese patients on MTX treatment is reported from before disease-modifying antirheumatic drug (DMARD) initiation till 20 months later. All consecutive DMARD-naïve RA patients (ACR 1987 criteria) attending the rheumatology unit of the University Hospital of Kinshasa from January 2008 to September 2010 were included. All were treated with MTX (started at 7.5 mg/week) and bridging steroids (started at 30mg/day). Treatment adaptations of MTX and concomitant drugs are reported as well as evolution of disease activity (DAS28-ESR), functionality (Health Assessment Questionnaire), radiological damage, and safety over 20 months. Of 98 patients recruited, more than one third were lost at follow-up. A follow-up visit at 20 months was available for 51 patients. These 48 women and 3 men had a mean age of 51.2 ± 13 years and a mean delay from symptom onset till their first visit of 3.2 years. At 20 months, the average MTX dose was 9.7 mg weekly. A second DMARD was added in three patients. The average dose of prednisone at 20 months was 7.5 mg daily. A significant improvement of DAS28 and functional disability was observed and 35.3 % of patients entered remission (DAS28 <2.6). A progression of X-ray damage was observed in one third of patients. Two patients had to stop MTX because of severe side effects and two patients developed diabetes. Methotrexate and bridging steroids therapy is effective also in sub-Saharan Africa but the average weekly MTX dose remains low. Implementation of a regular follow-up is a major issue.</div></front></TEI><affiliations><list><country><li>Belgique</li></country></list><tree><noCountry><name sortKey="Malemba, J J" sort="Malemba, J J" uniqKey="Malemba J" first="J. J." last="Malemba">J. J. Malemba</name><name sortKey="Mbuyi Muamba, J M" sort="Mbuyi Muamba, J M" uniqKey="Mbuyi Muamba J" first="J. M." last="Mbuyi Muamba">J. M. Mbuyi Muamba</name><name sortKey="Mukaya, J" sort="Mukaya, J" uniqKey="Mukaya J" first="J." last="Mukaya">J. Mukaya</name></noCountry><country name="Belgique"><noRegion><name sortKey="Bossuyt, X" sort="Bossuyt, X" uniqKey="Bossuyt X" first="X." last="Bossuyt">X. Bossuyt</name></noRegion><name sortKey="Verschueren, P" sort="Verschueren, P" uniqKey="Verschueren P" first="P." last="Verschueren">P. Verschueren</name><name sortKey="Westhovens, R" sort="Westhovens, R" uniqKey="Westhovens R" first="R." last="Westhovens">R. Westhovens</name><name sortKey="Westhovens, R" sort="Westhovens, R" uniqKey="Westhovens R" first="R." last="Westhovens">R. Westhovens</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001145 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001145 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AB2D15A11890979C03CDDE657DF5F5251C5549BA
|texte= Treatment of rheumatoid arthritis with methotrexate in Congolese patients
}}
| This area was generated with Dilib version V0.6.33. |  |